C4 Therapeutics (CCCC) Competitors $1.62 -0.02 (-0.91%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC vs. ABVX, AUTL, ETON, RVNC, RAPP, AMLX, ZVRA, MREO, ALT, and KMDAShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include ABIVAX Société Anonyme (ABVX), Autolus Therapeutics (AUTL), Eton Pharmaceuticals (ETON), Revance Therapeutics (RVNC), Rapport Therapeutics (RAPP), Amylyx Pharmaceuticals (AMLX), Zevra Therapeutics (ZVRA), Mereo BioPharma Group (MREO), Altimmune (ALT), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. ABIVAX Société Anonyme Autolus Therapeutics Eton Pharmaceuticals Revance Therapeutics Rapport Therapeutics Amylyx Pharmaceuticals Zevra Therapeutics Mereo BioPharma Group Altimmune Kamada ABIVAX Société Anonyme (NASDAQ:ABVX) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations. Which has more volatility & risk, ABVX or CCCC? ABIVAX Société Anonyme has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.11, meaning that its stock price is 211% more volatile than the S&P 500. Do insiders & institutionals believe in ABVX or CCCC? 47.9% of ABIVAX Société Anonyme shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 8.6% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer ABVX or CCCC? In the previous week, ABIVAX Société Anonyme had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for ABIVAX Société Anonyme and 3 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 1.21 beat ABIVAX Société Anonyme's score of 1.07 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABIVAX Société Anonyme 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ABVX or CCCC? ABIVAX Société Anonyme currently has a consensus target price of $34.00, indicating a potential upside of 387.80%. C4 Therapeutics has a consensus target price of $12.50, indicating a potential upside of 669.23%. Given C4 Therapeutics' higher probable upside, analysts plainly believe C4 Therapeutics is more favorable than ABIVAX Société Anonyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABIVAX Société Anonyme 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is ABVX or CCCC more profitable? ABIVAX Société Anonyme has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. ABIVAX Société Anonyme's return on equity of 0.00% beat C4 Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ABIVAX Société AnonymeN/A N/A N/A C4 Therapeutics -313.35%-42.45%-27.55% Which has stronger earnings and valuation, ABVX or CCCC? C4 Therapeutics has higher revenue and earnings than ABIVAX Société Anonyme. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioABIVAX Société AnonymeN/AN/A-$159.90MN/AN/AC4 Therapeutics$35.58M3.24-$132.49M-$1.51-1.08 Does the MarketBeat Community favor ABVX or CCCC? C4 Therapeutics received 17 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. However, 76.92% of users gave ABIVAX Société Anonyme an outperform vote while only 38.57% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformABIVAX Société AnonymeOutperform Votes1076.92% Underperform Votes323.08% C4 TherapeuticsOutperform Votes2738.57% Underperform Votes4361.43% SummaryC4 Therapeutics beats ABIVAX Société Anonyme on 8 of the 15 factors compared between the two stocks. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$115.39M$2.96B$5.49B$7.97BDividend YieldN/A1.89%5.11%4.23%P/E Ratio-0.9630.2622.6118.58Price / Sales3.24494.29397.51103.15Price / CashN/A168.6838.1834.62Price / Book0.403.166.704.26Net Income-$132.49M-$72.35M$3.22B$248.31M7 Day Performance0.93%0.81%1.26%1.34%1 Month Performance13.24%8.04%3.73%3.92%1 Year Performance-75.15%-22.95%15.82%5.33% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics2.4306 of 5 stars$1.63-0.9%$12.50+669.2%-74.0%$115.39M$35.58M-0.96150Upcoming EarningsNews CoveragePositive NewsABVXABIVAX Société Anonyme2.3916 of 5 stars$6.23-2.7%$38.00+510.0%-52.5%$395.10MN/A0.0061Analyst ForecastNews CoveragePositive NewsAUTLAutolus Therapeutics2.7213 of 5 stars$1.44+0.7%$9.32+547.2%-61.7%$383.18M$10.12M-1.19330Upcoming EarningsPositive NewsGap DownETONEton Pharmaceuticals2.5404 of 5 stars$14.26-0.6%$27.67+94.0%+381.4%$382.43M$39.01M-64.8220Upcoming EarningsAnalyst RevisionNews CoverageRVNCRevance Therapeutics2.4653 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500Upcoming EarningsRAPPRapport Therapeutics2.442 of 5 stars$10.38+2.3%$32.67+214.7%N/A$378.83MN/A-0.75N/AAMLXAmylyx Pharmaceuticals2.8572 of 5 stars$4.23+6.3%$8.00+89.1%+182.3%$374.79M$87.37M-1.11200Upcoming EarningsZVRAZevra Therapeutics2.7655 of 5 stars$6.87-3.9%$22.29+224.4%+60.0%$371.78M$23.61M-3.4920Upcoming EarningsNews CoveragePositive NewsMREOMereo BioPharma Group2.3399 of 5 stars$2.33+1.3%$7.71+231.1%-15.1%$370.47M$1M-38.8340High Trading VolumeALTAltimmune2.5889 of 5 stars$4.79+5.3%$20.83+334.9%-19.8%$368.90M$20,000.00-3.0950Upcoming EarningsNews CoveragePositive NewsKMDAKamada3.8893 of 5 stars$6.40-1.5%$14.67+129.2%+23.9%$367.87M$160.95M22.86360Upcoming EarningsShort Interest ↓ Related Companies and Tools Related Companies ABIVAX Société Anonyme Competitors Autolus Therapeutics Competitors Eton Pharmaceuticals Competitors Revance Therapeutics Competitors Rapport Therapeutics Competitors Amylyx Pharmaceuticals Competitors Zevra Therapeutics Competitors Mereo BioPharma Group Competitors Altimmune Competitors Kamada Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CCCC) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CCCC Stock Free CCCC Stock Alerts